Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Continuum architecture dynamics of vesicle tethering in exocytosis

  • Puig-Tintó, Marta
  • Ortiz, Sebastian
  • Meek, Sasha
  • Coray, Raffaele
  • Betancur, Laura I.
  • Hernández, Altair C.
  • Castellet, Anna
  • Kramer, Eric
  • Hoess, Philipp
  • Mund, Markus
  • Molina-Ribagorda, Andrés
  • Izquierdo-Serra, Mercè
  • Oliva, Baldo
  • Marco, Alex de
  • Ries, Jonas
  • Castaño-Díez, Daniel
  • Manzo, Carlo
  • Gallego, Oriol
[Data and code availability] All original code is available at https://github.com/GallegoLab. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PRIDE: PXD061766. Tomograms have been deposited to the EMPIAR database with the dataset identifier EMPIAR: EMPIAR-12989. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request., Essential for eukaryotes, multiple copies of the exocyst complex tether each secretory vesicle to the plasma membrane (PM) in constitutive exocytosis. The exocyst higher-order structure (ExHOS) that coordinates the action of these multiple exocysts remains unexplored. We integrated particle tracking, super-resolution microscopy, and cryo-electron tomography to time-resolve the continuum conformational landscape of the ExHOS and to functionally annotate its different conformations. We found that 7 exocysts form a flexible ring-shaped ExHOS that tethers vesicles at <45 nm from the PM. The ExHOS rapidly expands while pulling the vesicle toward the PM in a stepwise mechanism comprising three metastable states at 27, 18, and 5 nm from the PM. After fusion, Sec18 mediates the disassembly of the stationary ExHOS, a function that controls the rate of exocytosis. By resolving biophysical principles in situ, we reconstructed the spatiotemporal dynamics of the multimeric architecture controlling vesicle tethering in exocytosis., This work was supported by iNEXT-Discovery funding (PID: 24954), the Human Frontiers Science Program (HFSP) (grant RGP0017/2020), the Joan Oró AGAUR-FI grants (2024 FI-1 00552) of the Generalitat of Catalonia, the Fundación Biofísica Bizkaia, the Basque Excellence Research Centre (BERC) program of the Basque Government, and by Spanish Funding Agencies (PID2021-127773NB-I00, PID2021-127724OA-I00, PID2021-125386NB-I00, PID2021-127309NB-I00 and PID2024-162166NB-100 funded by MICIU/AEI/10.13039/501100011033/FEDER/UE and by “ERDF A way of making Europe”; the Unidad de Excelencia Maria de Maeztu [CEX2018-000792-M and CEX2024-001431-M]; and CNS2022-135349 funded by MICIU/AEI/10.13039/501100011033) and the Swiss National Fonds for Science (grant SNF 320030-236069). This research work was funded by the European Commission – NextGenerationEU, through the Momentum CSIC Programme: Develop Your Digital Talent grant IBF-01., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD109 Drives Stemness and Chemoresistance in Colorectal Cancer via LRRC8A/AKAP12/PKCα-Mediated STAT3 Activation and WNT Signaling

  • Bartolomé, Rubén Álvaro
  • Calvo-López, Tania
  • Otero-Núñez, Pablo
  • Estaras, María
  • Fernández-Barral, Asunción
  • Barbáchano, Antonio
  • Boukich, Issam
  • Cuerda-López, María
  • Fernández-Aceñero, Mª Jesús
  • Rodríguez-Urquirizar, Gorane
  • Mariscal-Casero, Ana
  • Padilla-Blanco, Miguel
  • Montoya, María
  • O'Loghlen, Ana
  • Fernández-Fernández, José M
  • Gonzalez-Sancho, Jose Manuel
  • Casal, J Ignacio
Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide, with a poor survival rate at the metastatic stage. Here, we identify CD109-a negative regulator of TGFβ signaling-as a key driver of stemness and drug resistance through modulation of Wnt signaling in advanced CRC. CD109 expression strongly correlates with TGFβ levels in patient tumors and is enriched in the aggressive CRIS-B subtype, where it associates with poor clinical outcome. CD109 silencing reduced STAT3 phosphorylation and cell proliferation, without affecting migration or invasion. Moreover, global expression analysis revealed downregulation of various hallmarks of cancer stemness (i.e. LGR5 expression), together with increased TGFβ signaling and cellular senescence. Mechanistically, CD109 interacts with LRRC8A, a subunit of the volume-regulated anion channel (VRAC), which associates with AKAP12 to activate PKCα and promote STAT3 phosphorylation. This CD109/LRRC8A/AKAP12/PKCα axis sustains Wnt signaling, stemness, and drug resistance. Consistently, co-expression of CD109/LRRC8A/AKAP12 correlates with poor prognosis in CRC patients. Genetic or pharmacological disruption of this CD109/LRRC8A/AKAP12/PKCα axis impaired STAT3 signaling, reduced LGR5 expression and Wnt signaling, and sensitized cells to chemotherapy. In vivo, CD109 or LRRC8A knockdown significantly impaired liver homing and metastatic colonization in mouse models, showing stronger effects in Swiss nude mice than in highly immunodeficient NSG mice. Collectively, these findings support CD109 as a central regulator for STAT3-driven stemness and chemoresistance in advanced CRC, via the LRRC8A/AKAP12/PKCα axis, and highlight its potential value as a therapeutic target in metastatic disease., PON was supported by a Juan de la Cierva contract from the Ministry of Science, Innovation and Universities (MICIU) (Spain). IB and MC were supported by IND2022/BMD-23554 and IND2024/ BMD-34329 fellowship grants of the Comunidad de Madrid. AMC was funded by a PhD fellowship Ramon Areces (BTVP25S22277). JMFF´s lab was funded by the Spanish Ministry of Science and Innovation (MCIN)/State Research Agency (AEI, Agencia Estatal de Investigación)/10.13039/ 501100011033/, and FEDER Funds (Fondo Europeo de Desarrollo Regional) (grant PID2022-136546OB-I00 to J.M.F-F); “Unidad de Excelencia María de Maeztu” CEX2024-001431-M, funded by MICIU/AEI/ 10.13039/501100011033. AO’s lab was supported by projects CNS2022-135134 and PID2021-125656OB-I00 financed by MICIU/AEI/10.13039/501100011033, 10.13039/501100011033 and by project SenesceX S2022/BMD-7393 financed by the Comunidad de Madrid. JIC´s lab was supported by grants PID2021- 122227OB-I00 and PID2024-156301OB-I00 (MICIU) with funds MCIN/AEI/10.13039/501100011033 and “Next-Generation EU”/PRTR, and grant S2022/BMD-7212 funded by the Comunidad de Madrid (Spain). Ethics approval and consent to participate The collection of patient-derived samples for, Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas, in vitro - Sistemas de cultivo - Cultivos 3D - organoides